I'm an infectious disease pharmacist at a large teaching hospital, and I'm witnessing a troubling increase in cases where we have to resort to last-line antibiotics due to antimicrobial resistance, particularly in gram-negative infections from the community. Our stewardship program focuses heavily on inpatient prescribing, but these resistant organisms are now coming in through the door, making our reactive strategies feel inadequate. For other stewardship teams, how are you expanding your focus beyond the hospital walls to address community drivers of resistance? What partnerships with primary care networks or long-term care facilities have been effective, and how are you communicating the urgency of this issue to non-specialist clinicians to change prescribing habits before it's too late?
You're not alone—there's a logic you can apply across settings. Start with a cross-setting stewardship scaffold: establish a joint team including hospital ID specialists, outpatient clinicians, pharmacists, and LTC/primary care partners; develop a shared antibiogram that covers hospital and community clinics; deploy an outpatient stewardship toolkit (delayed prescriptions, audit-and-feedback prompts, and pharmacist-led med-review); set 2–3 measurable targets (e.g., reduction in broad-spectrum use, increased appropriate therapy, improved return-visit outcomes).
90-day rollout plan for community-focused stewardship: 1) map your network—where patients are seen, labs used, and meds sourced; 2) sign MOUs with 2–3 PCP networks and 2 LTC facilities; 3) launch outreach and micro-trainings plus “stewardship rounds” in clinics; 4) implement a tele-ID consult or after-hours antibiotic advisory line; 5) begin standard data collection (outpatient days of therapy, drug costs, de-escalation rates); 6) review results and iterate.
Data sources and metrics that actually help: use NHSN Antimicrobial Use and Resistance modules, CDC AR Lab Network for trends, state dashboards, and local antibiograms; pool outpatient lab and pharmacy data to compute outpatient days of therapy per 1000 patient-days, proportion of guideline-concordant therapy, and 30-day readmission related to infection. Track at the setting level (ED, clinic, urgent care, LTC) and refresh quarterly.
Practical nonclinical tactics to influence prescribing: quick, targeted education for PCPs via case-based micro-trainings; promote delayed prescribing where appropriate; implement after-visit follow-ups via telemedicine to adjust therapy; share peer benchmarking feedback; provide visible decision-support prompts in the EHR.
Partnerships and sustainability: collaborate with community pharmacies for safe dispensing and antibiotic selection, partner with SNFs/LTCs on rider programs and infection control, engage schools or workplaces for vaccination drives to reduce infections, and seek grant funding for IT-enabled stewardship (clinical decision support, dashboards) and for dedicated time for pharmacists and CHWs to participate in outpatient stewardship. Consider a shared budget across hospital and community sites to support data sharing and joint audits.
Implementation note: start with a concrete pilot in a defined catchment (e.g., two clinics and one LTC) with 6–12 weeks of data collection, a simple dashboard, and a public progress update. If you want, tell me your hospital size, catchment demographics, and current data systems and I’ll tailor a 90-day rollout plan and a starter set of outreach materials.